Latest Ratios: P/E Ratio -1.6x · EV/EBITDA N/A · ROE -15.6%. (2000–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $21M | $23M | $21M | $33M | $54M | $237M | $358M | $49M | $19M | $22M | $27M |
| Enterprise Value | $19M | $21M | $18M | $22M | $37M | $212M | $344M | $46M | $13M | $10M | $15M |
| P/E Ratio → | -1.64 | — | — | — | 10.93 | 4.25 | 13.42 | 20.05 | — | — | — |
| P/S Ratio | 0.55 | 0.60 | 0.62 | 0.76 | 0.57 | 1.26 | 4.37 | 1.17 | 0.58 | 0.63 | 0.92 |
| P/B Ratio | 0.28 | 0.31 | 0.24 | 0.33 | 0.51 | 2.39 | 7.17 | 1.72 | 0.76 | 0.80 | 0.97 |
| P/FCF | — | — | — | 17.36 | — | — | — | 31.36 | — | — | — |
| P/OCF | — | — | — | 12.01 | 3.22 | 7.24 | 18.83 | 22.33 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.56 | 0.53 | 0.51 | 0.39 | 1.13 | 4.20 | 1.10 | 0.39 | 0.30 | 0.50 |
| EV / EBITDA | — | — | — | — | 9.94 | 2.88 | 13.81 | 11.98 | — | — | — |
| EV / EBIT | — | — | — | — | 6.99 | 2.83 | 13.06 | 13.78 | — | — | — |
| EV / FCF | — | — | — | 11.55 | — | — | — | 29.31 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.1% | 0.1% | -3.1% | 20.9% | 29.8% | 50.6% | 45.2% | 33.8% | 30.7% | 28.9% | 34.7% |
| Operating Margin | -52.8% | -52.8% | -63.9% | -26.4% | -0.9% | 38.5% | 29.4% | 7.1% | -4.0% | -11.0% | -11.8% |
| Net Profit Margin | -32.8% | -32.8% | -36.0% | -16.1% | 5.4% | 29.8% | 29.6% | 7.5% | -4.0% | -10.8% | -12.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -15.6% | -15.6% | -12.7% | -6.8% | 4.9% | 75.2% | 61.8% | 11.6% | -5.1% | -13.5% | -12.5% |
| ROA | -8.3% | -8.3% | -7.0% | -3.6% | 2.4% | 35.2% | 32.1% | 7.6% | -3.6% | -9.7% | -9.1% |
| ROIC | -19.3% | -19.3% | -18.4% | -9.7% | -0.8% | 98.7% | 58.8% | 10.1% | -5.7% | -17.9% | -16.2% |
| ROCE | -14.2% | -14.2% | -13.1% | -6.2% | -0.5% | 57.0% | 42.0% | 9.0% | -4.5% | -12.2% | -10.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 | 0.08 | 0.10 | 0.12 | 0.13 | 0.14 |
| Debt / EBITDA | — | — | — | — | 0.78 | 0.06 | 0.15 | 0.71 | — | — | — |
| Net Debt / Equity | — | -0.02 | -0.03 | -0.11 | -0.16 | -0.25 | -0.28 | -0.11 | -0.26 | -0.42 | -0.44 |
| Net Debt / EBITDA | — | — | — | — | -4.48 | -0.34 | -0.56 | -0.84 | — | — | — |
| Debt / FCF | — | — | — | -5.82 | — | — | — | -2.06 | — | — | — |
| Interest Coverage | -230.03 | -230.03 | -27.74 | -57.60 | 31.25 | 330.91 | 101.18 | 19.91 | -6.64 | -17.62 | -16.32 |
Net cash position: cash ($3M) exceeds total debt ($895645)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.57 | 6.57 | 8.34 | 8.28 | 7.32 | 2.96 | 2.49 | 3.44 | 2.79 | 3.37 | 3.72 |
| Quick Ratio | 4.78 | 4.78 | 6.16 | 6.41 | 5.61 | 2.38 | 2.12 | 2.54 | 1.91 | 2.58 | 2.74 |
| Cash Ratio | 3.85 | 3.85 | 5.08 | 5.04 | 4.07 | 1.20 | 0.92 | 1.66 | 1.25 | 1.88 | 2.26 |
| Asset Turnover | — | 0.27 | 0.21 | 0.24 | 0.45 | 0.88 | 0.78 | 0.91 | 0.90 | 0.90 | 0.77 |
| Inventory Turnover | 2.22 | 2.22 | 1.78 | 1.96 | 3.22 | 4.52 | 4.38 | 3.71 | 3.06 | 3.95 | 2.78 |
| Days Sales Outstanding | — | 78.33 | 96.81 | 99.02 | 67.29 | 79.02 | 146.74 | 57.76 | 54.99 | 54.02 | 39.99 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.1% | 1.0% | 1.1% | 0.7% | 0.5% | 1.6% | 0.1% | 0.4% | 1.1% | 1.0% | 0.8% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 9.1% | 23.5% | 7.4% | 5.0% | — | — | — |
| FCF Yield | — | — | — | 5.8% | — | — | — | 3.2% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 3.3% | 16.1% | 2.7% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.1% | 1.0% | 1.1% | 4.0% | 16.6% | 4.3% | 0.2% | 0.4% | 1.1% | 1.0% | 0.8% |
| Shares Outstanding | — | $30M | $30M | $30M | $33M | $34M | $33M | $33M | $33M | $32M | $29M |
Liquidity and operational insolvency
Trading at a price-to-sales multiple of 0.55x, RVP's valuation appears to be decoupled from industry peers, suggesting that the market is pricing the firm as a distressed asset rather than a viable medical device manufacturer with sustainable long-term growth prospects or reliable cash flow generation.
The current P/S multiple of 0.55x is significantly lower than diversified medical supply peers, which often trade at premiums due to their stable margins and recurring revenue models. This valuation gap implies that investors are heavily discounting the company's ability to return to profitability, viewing the stock primarily as a speculative option on potential government procurement rather than a fundamental business.
As reported in recent financial statements, RVP's ROIC has remained consistently negative, reaching -6.6% in 2026Q1, which highlights a persistent inability to generate returns on invested capital that exceed the cost of maintaining its domestic manufacturing footprint in a highly competitive, low-margin medical device market.
The negative ROIC trend over the last ten quarters suggests that every dollar invested in the business is currently destroying shareholder value rather than compounding it. This decay is driven by the company's inability to achieve sufficient operating margins to cover its fixed asset base, rendering the current capital allocation strategy ineffective.
Based on the provided quarterly data, the cash conversion cycle has remained elevated, peaking at 361 days in 2024Q2, which reveals significant working capital inefficiencies and a lack of leverage over suppliers and customers compared to larger, more dominant incumbents in the medical supply chain.
The high DIO (days inventory outstanding) of 212 days in 2026Q1 suggests that the company is struggling to move its product, potentially leading to obsolescence risks for its specialized VanishPoint inventory. This inefficiency ties up critical cash that the company cannot afford to lose given its current negative operating margins.
According to the latest balance sheet, the current ratio of 5.74x masks a deteriorating liquidity position, as the company's cash reserves have dwindled to $2.8M, leaving it increasingly vulnerable to operational shocks or the need for dilutive financing to sustain its ongoing negative cash flow.
While the current ratio appears high, it is heavily skewed by inventory that may be difficult to liquidate at book value in a distressed scenario. Investors should monitor the cash burn rate closely, as the current trajectory suggests that the company's liquidity runway is narrowing to a critical point.
The price-to-book ratio of 0.28x is frequently misapplied to RVP, as it suggests the stock is undervalued relative to its assets, while in reality, the book value is heavily comprised of specialized manufacturing equipment that may hold little liquidation value in a distressed operational environment.
Analysts should focus on the cash-to-burn ratio rather than P/B, as the latter ignores the reality that the company's primary assets are tied to a high-cost, low-margin production model. Relying on book value provides a false sense of security that ignores the underlying risk of operational insolvency.
Includes 30+ ratios · 26 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RVP stock.
Retractable Technologies, Inc.'s current P/E ratio is -1.6x. The historical average is 22.1x.
Retractable Technologies, Inc.'s return on equity (ROE) is -15.6%. The historical average is -11.5%.
Based on historical data, Retractable Technologies, Inc. is trading at a P/E of -1.6x. Compare with industry peers and growth rates for a complete picture.
Retractable Technologies, Inc.'s current dividend yield is 1.09%.
Retractable Technologies, Inc. has 0.1% gross margin and -52.8% operating margin.